Clinical Trial Update: Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial update on vedolizumab subcutaneous maintenance therapy for ulcerative colitis reports efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Colitis, Ulcerative | Phase 3 | Status: COMPLETED | Results posted: 2020-01-23